News for Kyverna Therapeutics Inc Stock (KYTX)

The Schall Law Firm Invites Kyverna Therapeutics Inc Investors To Join The Securities Fraud Investigation Into KYTX

Accesswire • 07/15/24

Investors Of Kyverna Therapeutics Inc Are Encouraged By The Schall Law Firm To Participate In The Securities Fraud Probe Into KYTX

Accesswire • 07/13/24

Kyverna Therapeutics Inc Investors Are Invited By The Schall Law Firm To Join The Securities Fraud Investigation Into KYTX

Accesswire • 07/12/24

Investors Of KYTX Are Welcomed By The Schall Law Firm To Participate In The Securities Fraud Investigation Into Kyverna Therapeutics Inc

Accesswire • 07/11/24

KYTX Investors Are Invited By The Schall Law Firm To Join The Securities Fraud Probe Into Kyverna Therapeutics Inc

Accesswire • 07/10/24

KYTX Investors Are Encouraged By The Schall Law Firm To Participate In The Kyverna Therapeutics Inc Securities Fraud Investigation

Accesswire • 07/09/24

KYTX Shareholders Are Encouraged By The Schall Law Firm To Participate In The Securities Fraud Investigation Into Kyverna Therapeutics Inc

Accesswire • 07/08/24

KYTX Investors Are Urged By The Schall Law Firm To Be Part Of The Securities Fraud Inquiry Into Kyverna Therapeutics Inc

Accesswire • 07/07/24

KYTX Stakeholders Are Encouraged By The Schall Law Firm To Participate In The Securities Deception Investigation Into Kyverna Therapeutics Inc

Accesswire • 07/06/24

KYTX Shareholders Are Invited By The Schall Law Firm To Join The Securities Fraud Probe Into Kyverna Therapeutics Inc

Accesswire • 07/03/24

The Schall Law Firm Is Conducting A Securities Fraud Investigation Into Kyverna Therapeutics Inc And Invites KYTX Shareholders To Participate

Accesswire • 07/02/24

Kyverna Therapeutics Inc And KYTX Stock Proprietors Are Welcomed To Engage In A Securities Fraud Examination Performed By The Schall Law Firm

Accesswire • 07/01/24

Kyverna Therapeutics Inc And KYTX Stock Possessors Are Requested To Be Part Of A Securities Fraud Inquiry Carried Out By The Schall Law Firm

Accesswire • 06/30/24

Kyverna Therapeutics Inc And KYTX Stock Holders Are Invited To Join A Securities Fraud Probe Conducted By The Schall Law Firm

Accesswire • 06/29/24

Kyverna Therapeutics Inc And KYTX Shareholders Are Invited To Be Involved In A Securities Fraud Probe Conducted By The Schall Law Firm

Accesswire • 06/28/24

The Schall Law Firm Is Undertaking A Securities Fraud Probe Into Kyverna Therapeutics Inc And Encourages KYTX Shareholders To Join

Accesswire • 06/27/24

Kyverna Therapeutics Inc And KYTX Stock Owners Are Encouraged To Participate In A Securities Fraud Investigation Led By The Schall Law Firm

Accesswire • 06/26/24

KYTX Shareholders Have The Opportunity To Participate In The Securities Fraud Investigation Of Kyverna Therapeutics Inc Led By The Schall Law Firm

Accesswire • 06/23/24

The Schall Law Firm Is Conducting A Securities Fraud Probe Into Kyverna Therapeutics Inc And KYTX Shareholders Are Invited To Be Involved

Accesswire • 06/22/24

KYTX Shareholders Can Join The Securities Fraud Investigation Of Kyverna Therapeutics Inc Conducted By The Schall Law Firm

Accesswire • 06/21/24

Shareholders Of KYTX Have The Opportunity To Participate In The Securities Fraud Scrutiny Of Kyverna Therapeutics Inc Led By The Schall Law Firm

Accesswire • 06/20/24

Kyverna's KYV-101 Receives U.S. FDA IND Clearance for Treatment of Patients With Treatment-Refractory Stiff-Person Syndrome in the KYSA-8 Phase 2 Trial

PRNewsWire • 06/20/24

Investors Of KYTX Can Join The Securities Fraud Investigation Of Kyverna Therapeutics Inc Conducted By The Schall Law Firm

Accesswire • 06/19/24

KYTX Investors Can Join The Securities Fraud Investigation Of Kyverna Therapeutics Inc By Schall Law Firm

Accesswire • 06/18/24

First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patient With Severe Stiff-Person Syndrome Published in Proceedings of the National Academy of Sciences (PNAS)

PRNewsWire • 06/17/24